title: [Combination therapy with 5'DFUR and MPA as a second line treatment for advanced/recurrent breast cancer].
abstract: As a second line therapy after failure to previous therapies, a combination therapy with MPA 1,200 mg po and 5'DFUR 1,200 mg po daily was given to 31 patients with recurrent breast cancer. At a median follow up period of 18 months, the overall response rate was 42%. The response rates for bone and visceral lesions were still good for the second line therapy. Patients previously exposed to tamoxifen (24 patients), 5-FU or its derivatives (21) and/or adriamycin (18) had response rates of 42%, 33%, 33%, respectively. The median duration of response in responders was 10 months. The overall median survival for the entire series was 9 months after start of the treatment. Thirteen (81%) of 16 patients with bone lesions were relieved from their bone pain. It is of special interest that the pain relief was also obtained in 7 out of 10 NC/PD patients with bone lesions, resulting in much improvement of their performance status. Side effects included obesity 52%, edema of the leg 35%, diarrhea 16% and so on. One patient developed venous thrombosis of her lower extremities and 4 were suspected to have the same condition. Fifty-five % of the patients underwent dose reduction of MPA at the 5th month of treatment in a median. This combination therapy is useful for recurrent disease even in late stages, so long as close observation is made for the occurrence of thrombosis.
authors: Department of Surgery, Center for Adult Diseases, Osaka.
authors: H
authors: H
authors: Koyama
authors: Y
authors: Y
authors: Nishizawa
authors: S
authors: S
authors: Noguchi
authors: H
authors: H
authors: Yamamoto
authors: K
authors: K
authors: Miyauchi
authors: H
authors: H
authors: Inaji
authors: S
authors: S
authors: Imaoka
authors: T
authors: T
authors: Iwanaga
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D005467:Floxuridine; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C025034:doxifluridine